3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
NIH
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Multiple Myeloma
4
Triple Negative Breast Neoplasms
1
Skin Neoplasms
1
Rhabdoid Tumor
1
Pancreatic Neoplasms
1
Oligodendroglioma
1
Neuroectodermal Tumors, Primitive
1
Melanoma
1
Medulloblastoma
1
Glioma
1
Diffuse Intrinsic Pontine Glioma
1
Brain Neoplasms
1
Astrocytoma
1
Interventions
Nivolumab
146
Ipilimumab
137
pembrolizumab
122
Cyclophosphamide
78
Interleukin-2
69
aldesleukin
63
Temozolomide
46
trametinib
37
Radiosurgery
37
Vemurafenib
36
fludarabine
34
Biopsy
34
dabrafenib
33
Radiotherapy
33
Blood Specimen Collection
31
fludarabine phosphate
30
sargramostim
27
Bevacizumab
27
Introns
23
Dacarbazine
22
Magnetic Resonance Spectroscopy
21
Specimen Handling
20
CTLA-4 Antigen
20
encorafenib
19
cobimetinib
19
binimetinib
19
Paclitaxel
19
Granulocyte-Macrophage Colony-Stimulating Factor
19
Cisplatin
17
incomplete Freund's adjuvant
15
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Melanoma
×
reolysin
×
Clear all
NCT03282188
2018-05-04
REO13 Melanoma With of Without GM-CSF
University of Leeds
Phase 1/2
Withdrawn